Extreme drug-tolerance in immunogenicity testing
Immunogenicity describes a drug´s ability to provoke an immune response in the body. While vaccines intend to create such an immune response, it is unwanted when directed against a therapeutic drug.
We provide support for assays using
• Anti-drug antibodies (ADA)
• Neutralizing antibodies (NAb)
Immune reactions are complex and responses can occur in a range between clinically not noticalble and life-threatening. We develop your assay tailored to your drug and disease and support your study before, during and after approval, since a routine monitoring can show drug efficiancy reduction after longer time periods.
Our ADA and NAb assays are based on the MSD™ technology, but we aim to establish cell-based assays soon.
Trade off immunoassay sensitivity for optimized drug-tolerance in immunogenicity testing.
Immunogenicity literature list
| Technology Comparison of Two Ligand-Binding Assay Platforms for Anti-Drug-Antibody Sample Testing Support for a Non-disclosed Lead Compound: MSD vs. Imperacer | request reprint |
| Immuno-PCR (IPCR) as Novel Tool for Improvement of Drug Tolerance in Immunogenicity Testing | |
| From ELISA to a Novel Immuno-PCR (I-PCR) based Immunogenicity Assay in Quest to Improve the Drug Tolerance | request reprint |
| Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes | |
| Immuno-PCR Assays for Immunogenicity Testing | |
| Feasibility of Immuno-PCR Technology Platforms as an Ultra Sensitive Tool for the Detection of Anti-Drug Antibodies |